AU Patent

AU2008284100A1 — Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2009-02-12 · 17y expired

What this patent protects

Patent listed against daclatasvir-dihydrochloride.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2008284100A1
Jurisdiction: AU
Classification: —
Expires: 2009-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Holdings Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.